Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457724 | 1.00 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL71181 | 1.00 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL73453 | 1.00 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL72787 | 0.92 | OPRD1 (0.64) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL72775 | 0.92 | OPRD1 (0.64) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL12569760 | 0.92 | OPRD1 (0.66) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL84143 | 0.92 | OPRD1 (0.66) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL9925787 | 0.90 | OPRD1 (0.72) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL84149 | 0.90 | OPRD1 (0.72) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL12569764 | 0.86 | OPRD1 (0.65) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | FREY JOSEPH (US) | 2012-07-12 | — | — | US | claimed |
| US-20120149717-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | BROWN WILLIAM (CA) | 2012-06-14 | — | — | US | claimed |
| US-8129393-B2 | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | claimed |
| EP-1781631-B1 | DIARYLMETHYL PIPERAZINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-01-25 | — | — | EP | claimed |
| EP-2296657-A1 | METHOD OF TREATING ANXIOUS MAJOR DEPRESSIVE DISORDER | AstraZeneca AB (SE) | 2011-03-23 | — | — | EP | claimed |
| US-20100168130-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | US | claimed |
| US-20090291966-A1 | Method Of Treating Anxious Major Depressive Disorder | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | claimed |
| WO-2009142587-A1 | METHOD OF TREATING ANXIOUS MAJOR DEPRESSIVE DISORDER | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | claimed |
| US-20070249619-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | claimed |
| US-20060030569-A1 | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | US | claimed |
| US-20250281513-A1 | USE OF PSYCHEDELICS TO TREAT DEMENTIA | MYND LIFE SCIENCES INC. (CA) | 2025-09-11 | — | — | US | disclosed |
| EP-4333857-A1 | USE OF PSYCHEDELICS TO TREAT DEMENTIA | Mynd Life Sciences Inc. (CA) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022204802-A1 | USE OF PSYCHEDELICS TO TREAT DEMENTIA | MYND LIFE SCIENCES INC. (CA) | 2022-10-06 | — | — | WO | disclosed |
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | FREY JOSEPH (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | FREY JOSEPH (US) | 2012-07-12 | — | — | US | disclosed |
| US-20090291966-A1 | Method Of Treating Anxious Major Depressive Disorder | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | US | disclosed |
| US-20070249619-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249619-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249619-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20060030569-A1 | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291966-A1 | Method Of Treating Anxious Major Depressive Disorder | DRD2, DRD4, HTR1D | OPRD1 22/4885KCNH2 1702/4885OPRM1 142/4885 |
| US-20120149717-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | OPRM1, OPRL1, PNMT | OPRD1 8/4885KCNH2 145/4885OPRM1 1/4885 |
| US-20120178763-A1 | Method of Treating Anxious Major Depressive Disorder | DRD2, DRD4, HTR1D | OPRD1 22/4885KCNH2 1702/4885OPRM1 142/4885 |
| US-20070249619-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | OPRM1, OPRL1, PNMT | OPRD1 8/4885KCNH2 145/4885OPRM1 1/4885 |
| US-20100168130-A1 | Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof | OPRM1, OPRL1, PNMT | OPRD1 8/4885KCNH2 145/4885OPRM1 1/4885 |
| US-20060030569-A1 | Diarylmethyl piperazine derivatives, preparations thereof and uses thereof | OPRM1, OPRL1, PNMT | OPRD1 8/4885KCNH2 145/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.